# A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.

> **NCT05167253** · PHASE1 · WITHDRAWN · sponsor: **United Biomedical Inc., Asia**

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** UB-612

## Key facts

- **NCT ID:** NCT05167253
- **Lead sponsor:** United Biomedical Inc., Asia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-02-15
- **Primary completion:** 2022-04-15
- **Final completion:** 2022-10-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Regulatory issues raised by the regulatory authority in Taiwan.
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05167253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05167253, "A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05167253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*